
A recent retrospective study investigates the effectiveness and safety of off-label calcitonin treatment in children with cherubism, a rare autosomal dominant disease characterized by jawbone lesions. The study, which includes nine patients, reveals that calcitonin treatment led to a significant reduction in the volume of cherubism lesions, with the most significant improvements observed in the initial six months of treatment. Although adverse effects were common, they were generally mild, with one case of severe symptomatic hypocalcemia. The findings suggest that calcitonin is a viable option for treating progressing cherubism in children, but further research is needed to refine treatment approaches.
Like
Save
Share